MyMD Pharmaceuticals Inc (MYMD): Test

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

MyMD Pharmaceuticals Inc (MYMD)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	25
Boards Moderated	0
Alias Born	04/07/2022

Re: SeanVan post# 422

Friday, 02/17/2023 7:20:26 AM

Friday, February 17, 2023 7:20:26 AM

Test

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent MYMD News

Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 01:04:23 PM
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer • Business Wire • 06/17/2024 01:00:00 PM
Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/31/2024 12:00:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 01:10:03 PM
MyMD Pharmaceuticals Secures Strategic Investments • Business Wire • 05/21/2024 01:00:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:01:08 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 04:00:19 PM
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • Business Wire • 03/05/2024 02:15:00 PM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:13:35 PM
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 04:27:33 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:57:03 PM
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • Business Wire • 02/13/2024 04:45:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:15:12 PM
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis • Business Wire • 12/06/2023 02:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 01:00:10 PM
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain • Business Wire • 10/19/2023 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 09:00:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 08:30:23 PM
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 • Business Wire • 10/04/2023 11:30:00 AM
Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:24:39 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/24/2023 09:58:33 PM

More MYMD News

InvestorsHub NewsWire

FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM

Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM

Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow